Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitodex is a chitosan-dextran (CD) hydrogel designed as a topical nasal and sinus dressing and a drug delivery vehicle. It is composed of succinyl-chitosan and dextran aldehyde, which cross-link to form a biocompatible, biodegradable biopolymer matrix. The product is FDA-approved for use following endoscopic sinus surgery (ESS) to prevent adhesion formation and reduce ostial stenosis. Beyond its role as a surgical dressing, Chitodex is utilized as a platform for the localized, sustained delivery of therapeutics such as budesonide (a corticosteroid) and mupirocin (an antibiotic), specifically for treating recalcitrant chronic rhinosinusitis (CRS). The gel provides a physical barrier and a sustained-release platform for localized drug delivery to the sinus mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chitodex.